Join us at the MarketsandMarkets Next-Gen Immuno-Oncology Conference - West Coast Edition, the premier gathering of leading experts and professionals in the field of immuno-oncology. Taking place on the 8th - 9th February 2024 in San Diego, USA, this conference is a must-attend event for anyone passionate about shaping the future of cancer treatment.

The Immuno-Oncology Conference brings together renowned researchers, clinicians, industry leaders, and policy makers to explore the latest advancements and breakthroughs in immuno-oncology. With a focus on next-generation approaches and cutting-edge innovations, the conference provides a platform for networking, knowledge exchange, and collaboration.

MarketsandMarkets presents the Immunobio Series, an extraordinary trio of conferences taking place on 8-9 February 2024 at DoubleTree by Hilton, San Diego Mission Valley.

MarketsandMarkets 9th Annual Biomarker and Companion Diagnostics Conference: Dive into the world of biomarkers at our flagship event, uniting experts and industry leaders to drive innovation in healthcare, diagnostics, and personalized medicine. Explore groundbreaking research and applications, fostering collaboration and knowledge sharing.

MarketsandMarkets 6th Annual Next Gen Microbiome and Probiotics Conference: Discover the future of microbiome therapies and probiotics. Engage with professionals from diverse sectors to explore microbial innovation, regulatory pathways, and the vital microbiome probiotics connection. Delve into cutting-edge research and strategies for successful commercialization.

MarketsandMarkets Next Gen Immuno-Oncology Conference: Explore the forefront of cancer treatment at our inaugural Immuno-Oncology Conference. Join researchers and industry experts to discuss advancements in ADCs, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors. Participate in discussions, share insights, and shape the future of immuno-oncology.

The microorganisms in a particular environment (including the body or a part of the body). 

We depend on a vast army of microbes to stay alive: a microbiome that protects us against germs, breaks down food to release energy, and produces vitamins. 

The human microbiome is the aggregate of all microbiotas that reside on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside, including the skin, mammary glands, placenta, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract, and gastrointestinal tract. Types of human microbiota include bacteria, archaea, fungi, protists, and viruses. 

MarketsandMarkets bring to you the 9th Annual Biomarker and CDx Conference - West Coast Edition scheduled to be held on 8th - 9th February 2024 in San Diego, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

MarketsandMarkets presents the Immunobio Series, an extraordinary set of conferences taking place on 7-8 March 2024 in London, UK.

Welcome to the 8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference, a premier event dedicated to advancing the field of immuno-oncology. Join us on 07th - 8th March 2024 in London, UK, where leading experts, researchers, and industry professionals will gather to shape the future of cancer treatment.

As a prominent Immuno-Oncology Conference, this event offers a unique platform to explore the latest advancements, breakthroughs, and innovations in the field. From antibodies and cellular therapies to immune-checkpoint research, our comprehensive program covers a wide range of topics, ensuring a holistic understanding of the dynamic landscape of immuno-oncology.

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

The healthcare sector is undergoing significant transformations, largely due to advancements in technology, and the Diagnostics field has emerged as a pivotal catalyst in this evolution. Given its crucial role in treatment decisions, diagnostics must strive for speed, precision, and accuracy.

Welcome to DeviceCon Series 2024 – Where Innovation Meets Impact!

Join us on March 21-22 in the vibrant city of London for a groundbreaking convergence of knowledge, ideas, and technology. MarketsandMarkets proudly presents the DeviceCon Series, an extraordinary blend of five conferences that promise to redefine the landscape of innovation in medical and diagnostic devices.

MarketsandMarkets is delighted to announce its Cancer Diagnostics Conference, scheduled to be held on 21st-22nd March 2024 in London. The conference is handcrafted to platform new cancer diagnostics insights, holding discussions on trending technologies along with its latest applications, indicating the challenges in the cancer diagnostics area covering, diagnostic setting, sample processing, regulations, validations, high technology cost, challenges involved in blood – transfusion technology, liquid biopsy, what needs to happen to facilitate better healthcare throughout the world, how therapies work and their side-effects, challenges associated with testing, issues with accuracy & the results.

Digital pathology has developed into a well-known technology in recent years. globally concentrated on human pathology practise, tissue-based research, drug development, and education.

MarketsandMarkets is extremely delighted to announce its "MarketsandMarkets 2nd Annual Next-Gen Digital Pathology Conference" scheduled to be held on 21st – 22nd March 2024. The conference will feature interactive sessions on topics such as slide-free imaging as a new method for studying histology, enterprise-wide solutions, the use of AI and ML in clinical research and primary diagnosis, and how the laboratory is changing as a result of image-based information environments that address a variety of medical issues. The conference offers fantastic chances for networking and idea sharing through engaging keynotes, posters, colloquia, workshops, and the Young Researchers Forum.

The field of surgery has undergone a revolutionary transformation with the introduction of new technologies and surgical techniques. One significant advancement is the utilization of robotic systems such as the Da Vinci system, which has greatly enhanced minimally invasive surgery (MIS). As a result, MIS has become the standard of care across various clinical specialities worldwide.

MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21–22, 2024, in London, UK. With the increased risk of infection due to improper sterilisation and decontamination practices, the safety of patients and healthcare workers is of paramount importance nowadays. This conference aims to bring together all the stakeholders to discuss the obstacles in achieving and maintaining an infection-free environment in the hospital and outpatient settings, as well as effective and research-based ways to reduce the risks of the outbreak of healthcare-associated infections through microbes and medical equipment because of subpar infection prevention and control methods and contaminated medical devices.
With this, it also gives experts a platform to share their views on comparing newly developed automated cleaning procedures with manual cleaning practices through interactive panel discussion sessions.

Looking and the current market scenario, many companies are outsourcing the manufacture of their highly potent compounds for various reasons, mainly marketing. The escalation in the High Potent drug market is subjected to a variety of aspects such as the diversification of pharmaceutical manufacturers towards precision medicines such as HPAPI, increasing demand for oncology drugs & antibody-drug conjugates, and advancements in HPAPI manufacturing technologies.

Looking and the current market scenario, many companies are outsourcing the manufacture of their highly potent compounds for various reasons, mainly marketing. The escalation in the High Potent drug market is subjected to a variety of aspects such as the diversification of pharmaceutical manufacturers towards precision medicines such as HPAPI, increasing demand for oncology drugs & antibody-drug conjugates, and advancements in HPAPI manufacturing technologies.

MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 20th - 21st June 2024 in Boston, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

Our 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 20th - 21st June 2024, in Boston, USA would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in the development of ADCs, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

MarketsandMarkets brings to you the 2nd Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 3rd-4th Oct 2024 in Frankfurt, Germany. This event is designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.

MarketsandMarkets is proud to announce the 7th Annual Real-World Evidence and Life Sciences Conference to be held on October 17th - 18th, 2024 in Boston, USA

In the world of modern healthcare, diagnostic imaging is a cornerstone of precision medicine. With over 5 billion imaging procedures conducted globally each year, the potential to determine clinical actions and monitor therapy outcomes is immeasurable. The future of diagnostic imaging holds immense promise, marked by the integration of artificial intelligence (AI) and machine learning (ML) technologies, evolving ecosystems, and continuous innovation.

In recent years, digital pathology has become a well-established technology. Globally focused on education, tissue-based research, medication development, and human pathology practice.

MarketsandMarkets is proud to announce the 6th Annual Real-World Evidence and Life Sciences Conference to be held on October 16th - 17th, 2023 at Hampton Inn by Hilton Boston Seaport District.

Real-world data and real-world evidence are poised to keep making strides in 2023.
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be extremely useful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while assisting to organize and evaluate clinical data for regulatory submissions.

The fundamentals of Single Cell have proven to be an indispensable resource in the sphere of medical research and new diagnostic strategies. Recent advances in single cell technologies have opened new opportunities to signify the intra-tumor cell heterogeneity, identify rare cell kinds, degree of mutation, and ultimately guide diagnosis and treatment option.

With the enforcement of the 1983 Orphan Drug Act (ODA), manufacturers are obliged to scale production to treat rare/orphan diseases, leading to a drastic advancement in the landscape of orphan drugs. Novel therapies aimed at treating these uncommon diseases are paramount to fulfilling the unmet needs of patients.

With the advent of neural implants and novel therapies, the cure of multiple neurodegenerative disorders proves wholesome for the patients’ suffering. Increasing in the severity of neurodegenerative diseases, demands the discovery of new translational approaches in neuroscience research.

Over the past 6 years, Marketsandmarkets Next-Gen Immuno-Oncology conference has become the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncology. Marketsandmarkets IO congress provides access to a comprehensive 2-day program for participants to evaluate bi- or multi-specific biotherapeutics, explore the latest developments in existing and emerging cellular therapies, develop predictive preclinical models for translational strategies, appraise AI and computational tools for the discovery of new targets, target classes, and combinations to overcome resistance.

MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 5th-6th October 2023 at The Westin Grand Frankfurt, Germany. This event is designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.

Real-world data and real-world evidence are poised to keep making strides in 2023. This analysis of clinical evidence studies the usage, potential advantages and risk of a medical product inferred from the real-world data analysis. Real-world evidence (RWE) is accelerating its involvement in the early benefit elucidation of medicinal drugs.

The fundamentals of Single Cell have proven to be an indispensable resource in the sphere of medical research and new diagnostic strategies. Recent advances in single cell technologies have opened new opportunities to signify the intra-tumor cell heterogeneity, identify rare cell kinds, degree of mutation, and ultimately guide diagnosis and treatment option.

Our 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, at Hilton Boston Logan Airport, Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 22nd - 23rd June 2023 at Hilton Boston Logan Airport, Boston, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

With the advent of new technological advancements in medical research and diagnostic strategies, early disease diagnosis and prevention has witnessed a medical revolution.

We are proud to present to you our ‘BioGene’ ConfEx in Boston scheduled on 22-23 June 2023 at Hilton Boston Logan Airport. This ConfEx is an assemblage of 3 inextricably linked conferences like Next-Gen Immuno-Oncology Conference, Biomarker and Companion Diagnostics and Single-Cell Omics Conference which will accommodate diverse sessions on cutting edge discussions via Presentations, Exhibitions, Speaker QnAs, Panel discussions or Breakout sessions.

Looking and the current market scenario, many companies are outsourcing the manufacture of their highly potent compounds for various reasons, mainly marketing. The escalation in the High Potent drug market is subjected to a variety of aspects such as the diversification of pharmaceutical manufacturers towards precision medicines such as HPAPI, increasing demand for oncology drugs & antibody-drug conjugates, and advancements in HPAPI manufacturing technologies.
 

MarketsandMarkets is proud to announce it’s 7th Annual Infection Control, Sterilization & Decontamination in Healthcare Conference scheduled for 23-24 March 2023 in London, UK.

This Congress aims to bring together all the stakeholders, to discuss the challenges in achieving and maintaining an infection free environment in the hospital settings in addition to effective and evidence based ways to reduce the risks of the emergence of healthcare-associated infections through fomites and medical equipment because of substandard infection prevention and control practice and contaminated medical devices.

It has been evident that for the past few decades there have been advances in Diagnostic technologies which have opened doors for early diagnosis & prevention.
MarketsandMarakets is proud to present to you the 4th Annual MarketsandMarkets Infectious Diseases and Molecular Diagnostics, scheduled to be on 23rd – 24th March 2023, in London. The event is created and shaped with presentations on the topics like Future Molecular Diagnostics and New Diagnostic Technologies, how the timely recognition of various viral diseases would prevent the spread to a great extent by use of Advanced Diagnostic Technologies, advances in lab-on-a-chip technologies, and many more.

Globally focused on education, tissue-based research, medication development, and human pathology practice. 

MarketsandMarkets is here with a platform for Scientists, Microbiologists, Biologists, Pathologists and Researchers to come together at the PathDx 2023 Confex on 23rd – 24th March 2023 in London. An opportunity to discuss future insights, innovations and research ideas with advanced solutions to the most challenges in infectious disease diagnostics, molecular diagnostics and digital pathologies verticals.

With the advent of new technological advancements and surgical techniques, minimally invasive surgery has witnessed a robotic revolution in the field of surgery in the form of Da Vinci robotic systems making MIS procedures a widely accepted standard of care for most of the clinical specialities all over the world. We are proud to present to you our 2nd Annual MarketsandMarkets Minimally Invasive Surgery Conference (6 streams) in London, scheduled on 20th – 21st March 2023.

Our 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 9th - 10th March 2023, in London, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

With the advent of new technological advancements in medical research and diagnostic strategies, early disease diagnosis and prevention has witnessed a medical revolution. We are proud to present to you our ‘OncoGene’ ConfEx in London scheduled on 9th – 10th March 2023. This ConfEx is an assemblage of 3 inextricably linked conferences like 7th Annual Next-Gen Immuno-Oncology Conference, Next-Gen Genomics and Proteomics Conference and Precision Medicine Conference which will accommodate diverse sessions on cutting edge discussions via Presentations, Exhibitions, Speaker QnAs, Panel discussions or Breakout sessions.

The healthcare sector is accelerating on a trajectory from ubiquitous treatment to truly personalized treatment. The advent of precision medicine has paved ways for customization and preventive health strategy development by utilizing the genetic information of the individual along with ethnicity, environment exposures, medical history and more. Surging trends in tailoring care have been a driving force for extensive research in this field from data research to target drug discovery.

Leading our way back to the ambitious research collaboration, Human Genome Project has paved ways in transforming biology and biological discovery. As a result of which, the fundamentals of Genomics and Proteomics have proven to be an indispensable resource in the sphere of medical research and new diagnostic strategies. The swift growth in high throughput technologies used for genomic and proteomic profiling has factored breakthroughs for a much-anticipated personalized medicine approach for complex diseases.

The ecology of human microbiome is known to be associated with both phenotype and environment. With the increasing focus on the development of human microbiome therapies and probiotics product & drug development various small innovative players are operating in the market.

However, inadequate research and regulatory policies in the human microbiome are some of the factors which restrain the progress. Learn about microbial innovation and applying the new microbiome findings along with the regulatory pathways for better therapeutic development. Also, witness discussions on microbiome vs probiotics and the link between them.

MarketsandMarkets is here with a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2023 Confex on the 8th - 9th February 2023 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.

MarketsandMarkets bring to you the 8th Annual Biomarker and CDx Conference scheduled to be held on 8th - 9th February 2023 in San Diego, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

Over the last 50 years, the bioprocessing industry has witnessed tremendous change, overcoming many challenges to increase efficiency and productivity throughout the development and manufacturing process. These efforts have been particularly focused to elicit major advancements for cell lines, culture media, and downstream processes used to produce therapeutics.

MarketsandMarkets is proud to announce the 5th Annual Real-World Evidence and Life Sciences Conference to be held on October 20-21, 2022 in Boston, USA.

Real-world data and real-world evidence are poised to keep making strides in 2022.
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be extremely useful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while assisting to organize and evaluate clinical data for regulatory submissions.

MarketsandMarkets is proud to announce the 3rd Annual MarketsandMarkets World Pharma Supply Chain and Cold Chain Logistics Virtual Conference on 20th-21st October 2022

Pharmaceutical supply chain and logistics faced the hardest disruptions during initial COVID era. Now, with COVID therapeutic manufacturing taking space, there also is a big desire to accelerate other clinical pipeline because of the ample opportunity for new medicine. While some companies were able to cope with their contingencies plan in place, the other followed risk mitigation. It is now essential for the pharma supply chain and logistics to follow the redundancy routes.

Emerging agricultural trends involve new technologies and strategies that become more advanced over time. There have been significant changes in the agriculture sector over the past several decades and new technologies have also been introduced. All these factors have led to an expansion of the sector. Recent agricultural advances have made farming activities more comfortable and acceptable for farmers. Developments or trends such as these benefit not only the growth of agriculture, but also the lives of farmers.

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

Over last several years, there has been a rapid development of technologies, methods, and applications of Single-Cell Analysis. Recent advances in single cell technologies have opened new avenues to signify the intra-tumor cell heterogeneity, identify rare cell kinds, degree of mutation, and ultimately guide diagnosis and treatment option. Single-cell sequencing is one of the most promising methods to study the tumor cells in cancer progression. These technologies have progressed intensely, and vigorously over the past five years.

Witness an overwhelming participation of the key decision makers from academia, pharmaceutical and bio-pharmaceutical industies working in the areas of research and development, manufacturing, market access, commercialization and supply chain under one roof.

MarketsandMarkets’ Biopharma Series is a platform providing an opportunity to experts from the industry, regulators, academia and technology providers to discuss innovations, challenges, best practices, use-cases and future aspects in the area of single cell analysis and next-gen immune-oncology.

Over last several years, there has been a rapid development of technologies, methods, and applications of Single-Cell Analysis. Recent advances in single cell technologies have opened new avenues to signify the intra-tumor cell heterogeneity, identify rare cell kinds, degree of mutation, and ultimately guide diagnosis and treatment option. Single-cell sequencing is one of the most promising methods to study the tumor cells in cancer progression. These technologies have progressed intensely, and vigorously over the past five years.

Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 23rd-24th, June 2022, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

MarketsandMarkets is providing a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2022 Confex on the 16th - 17th June 2022 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.

With growing pressures of increasing success rates for FDA approved biomarkers as well as companion diagnostics tests has seen an outgrowth in drug discovery companies to invest in novel strategies for biomarker discovery. The industry of genome editing has witnessed some great breakthroughs during a year in the areas like genome writing, base editing and specific progression in the field of therapeutics through the Car-T cells and immunotherapy.  With the increasing focus on the development of human microbiome therapies and probiotics product &drug development various small innovative players are operating in the market.

One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations. 

Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries.

The Diagnostics sector has emerged as a prominent game changer in healthcare, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions, it needs to be quicker, précised, and accurate.

MarketsandMarkets is extremely delighted to announce its 3rd Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference scheduled to be held on 23rd - 24th March 2022 in London.

Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection and urinary tract infection.

New medicine for Orphan and Rare Diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.

The advancement of delicate CTC and cfDNA identification led to innovations that has empowered the improvement of liquid biopsies with numerous clinical applications, including-screening for nearness of disease, patient stratification and treatment determination,monitoring treatment reaction and early diagnostics.

The treatment options for cancer, such as chemotherapies and radiation therapy, although have more side effects, are more widely used as compared to immunotherapies. The former are all based on destroying cancer cells by irradiation, chemotherapy, or surgery. While they can effectively kill or remove cancer cells, the use of these treatments is often limited because they tend to destroy healthy cells in large numbers as well. As immunotherapies involve the mechanism of enhancing the body’s own immunity using man-made proteins such as monoclonal antibodies, they are accepted worldwide over other treatment options.

In recent years, there has been an extraordinary leap in knowledge of the human genome and its role in health and disease. Advanced genetic sequencing has been revolutionizing discoveries across life sciences and has been accelerating technology that offers ultra-high throughput, scalability, and speed in modern medicine

Single-cell analysis is crucial for discovering population heterogeneity, identifying minority sub-populations of interest, and discovering unique properties of individual cells. Microfluidic systems operate on a scale comparable to cell width and are capable of manipulating single cells. Single-cell sequencing is a new and powerful technique for studying the evolution and variety of most malignancies, as well as the involvement of circulating tumour cells in cancer progression. These techniques have begun to answer critical problems in cancer biology that have been difficult to answer using bulk tumour measurements. The technology and applications of single-cell analysis have advanced dramatically in the last five years.

Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. There are still factors like manufacturing maze, investment, logistics and regulatory challenges which prevents the cell and gene therapies to be widely used. We are once again putting together a unique platform to provide the exact solutions to these robust manufacturing and bioprocessing challenges, at our 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference.

Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress to be held on 26 - 29 October 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

Boston Scientific is excited to launch their first ‘Partnering for Prevention’ event, a 3-hour virtual interaction discussing the ever-important topic, Infection Control in Endoscopy.

MarketsandMarkets is proud to announce the 5th Edition Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 20-22, 2021. The expanding utilization of Real World Evidence to speed up data driven choices is further developing the clinical trial experience, but healthcare in general. 

While there is extraordinary promise in utilizing Real World Data and Real World Evidence, there are some significant challenges that should be survived: potential bias of information and data sources, inadequate data sets and absence of harmonization of data between RWE data sources, access to such data, and lack of standards in evaluating the worth of Real World Evidence data. Further developing RWE is key for pharma organizations in drug development. There was big data available pre covid and now with the access data due to covid, technology enablers like AI and ML are important for big data analysis and evidence generation. Every stakeholder has faced a some impact and had to adjust. 

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

The pandemic has disrupted healthcare systems frameworks around the world, with hospitals being overwhelmed due to the increasing influx of patients. The spread of COVID-19 has prodded a surge in demand for cleaning and disinfection products due to the growing awareness about hygiene, health, and safety. The increasing healthcare expenditure in North America being the major factor driving the demand and uptake of antiseptics and disinfectants in the region.

The utilization of reprocessed equipment to disinfect or sterilize medical devices is higher than normal now since improper decontamination of surgical instruments, endoscopic devices, respiratory care devices, and reusable hemodialysis machines can increase the chances of healthcare associated infections. Patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilizing medical devices.

The pandemic has disrupted healthcare systems frameworks around the world, with hospitals be-ing overwhelmed due to the increasing influx of patients. The spread of COVID-19 has prodded a surge in demand for cleaning and disinfection products due to the growing awareness about hy-giene, health, and safety.

The utilization of reprocessed equipment to disinfect or sterilize medical devices is higher than normal now since improper decontamination of surgical instruments, endoscopic devices, respira-tory care devices, and reusable hemodialysis machines can increase the chances of healthcare as-sociated infections. Patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilising medical devices

Nanopore sequencing and its application to pandemic epidemiological survey of SARS CoV-19 and strains surveillance. Now, with COVID therapeutic manufacturing taking priority, there is a big desire to accelerate other clinical pipeline because of ample opportunity for new medicine.

MarketsandMarkets is proud to announce the Advanced Genetic Sequencing Virtual Conference scheduled to be held on 23-24 September 2021 will hold discussions on trending technologies and its applications, challenges of implying these technologies into clinical specimen, practice of sequencing in healthcare domain specifically to cancer cells, overview of the data used in these technologies and its applications. This event will witness an overwhelming participation of leading healthcare and industry decision makers.

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-US Edition to be held on 28th-1st July 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

Pharmaceutical supply chain and logistics faced the hardest disruptions during initial COVID era. Now, with COVID therapeutic manufacturing taking priority, there also is a big desire to accelerate other clinical pipeline because of the ample opportunity for new medicine. While some companies were able to cope with their contingencies plan in place, the other followed risk mitigation. It is now essential for the pharma supply chain and logistics to follow the redundancy routes.  

After the successful foureditions of Bioprocessing of Cell therapies, coming up with 5th Annual of Bioprocessing of Biotherapeutics brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development, manufacture and quality of protein expressions, cell, and gene therapies.

The virtual event will present detailed case studies and interactive discussions in cell culture, scale-up, continuous processing, recovery, purification, process and product characterization, and formulation.

MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April, 2021.

While the 3rd annual virtual conference had discussions on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19.

As per MarketsandMarkets research analysis, the global dPCR and qPCR is estimated to grow to USD 6,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use.

Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection and urinary tract infection.

The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 - 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. 

One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations. 

Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries.

The Diagnostics sector has emerged as a prominent game changer in healthcare, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions, it needs to be quicker, précised, and accurate.

Witness the significant development of microbiome, probiotics and prebiotics research alongside their applications relating to difficulties like therapeutic information understanding, speculation and administrative obstacles looked by the experts. The convergence between developing innovation and disclosure with the setting of consumer intrigue. Recognize the non-distinguished dysbiosis, to find the expected territories under examination for interests in Gut and Skin microbiome and its part as an indicative instrument of drug revelation. 

New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.

Single-cell sequencing (SCS) is new effective tool for investigating the evolution and variety of most cancers and role of circulating tumor cells in cancer progression. These methods have started to unravel key questions in cancer biology which have been hard to deal with for bulk tumor measurements. Over the span of 5 years, there has been exceptional development in technology and applications of Single-cell analysis.

Recent advances in single cell technologies have opened new avenues to signify the intra-tumor cell heterogeneity, identify rare cell kinds, degree of mutation, and, ultimately guide diagnosis and treatment option.

MarketsandMarkets is proud to announce the Pharma Cold Chain Logistics - Virtual Conference to be held on 5th - 6th November 2020. Increasing pressure faced by pharmaceutical companies to make their supply chain more efficient, cost effective, focused and more agile has made the industry increasingly competitive in the recent years. With the wide consumption of cold chain logistics in the pharmaceutical industry, efficient temperature controlled logistics is mandatory for quality assurance of drugs. Now with the additional road-blocks and problems due to the pandemic, the pharma supply chain is faring, specifically transportation.

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

Around 1 in 20 (6%) of patients are affected by preventable harm in medical care, of which around 12% causes permanent disability or death, according to a study published by The BMJ. These infections are contracted by an estimated 1.7 million patients annually and responsible for 99,000 deaths each year.

Preventing disease and controlling spread of resistant bacteria is of major importance when tackling antibiotic resistance.  Already, AMR infections are estimated to cause 700,000 deaths each year globally, which is predicted to rise to 10 million, alongside a cumulative cost of $100 trillion, by 2020 if no action is taken.

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

MarketsandMarkets is proud to announce the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 22nd -23rd, 2020.

While the 2nd annual Congress had discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation, the 3rd Annual will focus on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers.

The Biosimilars industry is experiencing significant growth due to the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness.

The global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. However, with complexities in manufacturing and resistance from biologic manufacturers, such factors keeps adding to the hinderance in their development.

Point-of-care testing (POCT) is a growing technology. Today, you may see POCT in a hospital with hand held gadgets or small testers in emergency department, extensive care setting, popular clinical wards and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient's point of care.

The cytotoxic nature of HPAPIs presents significant handling challenges and thus requires heavy investments for implementing specialized containment facilities that facilitate the safety of employees from exposure. Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. 

One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations. 

MarketsandMarkets is proud to announce the 4th Annual High Potent Medicines Conference to be held on 14th - 15th September 2020 . This conference would address the challenges in the continual evolution of industry standards, technologies, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations, live case studies and breakthrough panel discussions.

New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.

MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 9th -10th July 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally-renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.

 

Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. In our conference of 2017, we assessed the specific risks and benefits of the cell culture and cell therapy bio-manufacturing for the cure of these diseases.

Due to growing concerns about COVID-19, the 3rd Annual MarketsandMarkets Next Gen IO Congress is going fully virtual this year. We are disappointed that we are not able to come together in person in June for this event, but we are so thrilled to see you on an online platform. We are working together to create a virtual conference that will be beneficial and engaging for speakers, attendees and sponsors/exhibitors.

See the Post Show report of our 2nd Annual here

Increasing pressure faced by pharmaceutical companies to make their supply chain more efficient, cost effective, focused and more agile has made the industry increasingly competitive in the recent years. With the mandate for serialization, strict quality regulations and increasing importance of patient centricity for pharma companies to follow, it is essential to navigate from complex supply chain ecosystem to simpler processes. Now with the additional roadblocks and problems due to the pandemic (global outbreak), the pharma supply chain is faring. Major problem being the  impact of COVID-19 on two of the largest global producers of active pharmaceutical ingredients (APIs) and generics: China and India.

Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.

See the Post Show report of our inaugural event here

As the era of personalized medicine is fast approaching, healthcare is becoming more personalized and tailored to the patient. Digital health platforms has helped converting medical data into a continuous, reliable and complete picture of the patient's health, and data analytics algorithms process information that is specific to individuals, leading to more personal and effective solutions.

MarketsandMarkets are proud to host its inaugural “Digital Transformation and Precision Medicine Virtual Conference” which will be held on 11th-12th June 2020.  The conference will focus on the innovative and disruptive digital health technologies and futuristic business models transforming the precision medicine industry. The conference further aims in bringing experts from the academics, pharma, start-ups, hospitals and technology providers who will share their recent technological breakthroughs in personalized medicine.

In recent years, the understanding regarding the role of epigenetic factors has been improved. Epigenetic research has been generally determined by technological advancement, remarkably high-throughput sequencing technologies. In spite of the fact that technologies have been improved and have been responsible for the advances in the field, several challenges remain.

Our 5th Annual Epigenetics- Digital Conference will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.

The advancement of delicate CTC and cfDNA identification led to innovations that has empowered the improvement of liquid biopsies with numerous clinical applications, including-screening for nearness of disease, patient stratification and treatment determination, monitoring treatment reaction and early diagnostics.

MarketsandMarkets Virtual Conference on Liquid Biopsy will unite the pioneers from Diagnostics organization, Experts from Pharmaceutical and Bio-Pharma companies, Researchers and professors from renowned universities to address the challenges in early detection of tumor cells and the potential of liquid biopsies to screen, monitor and treatment of the diseases.

According to a study published by The Lancet Infectious Diseases, researchers estimated that globally 3 in every 1,000 people carry latent multidrug-resistant tuberculosis (MDR-TB), with the prevalence of being 10 times higher among children younger than 15 years of age.

As outlined in the independent review on Antimicrobial Resistance, AMR is predicted to kill 10 million people every year by 2050 without action. From rare pathogens to pandemic prevention, explore the latest techniques and technologies that are shaping today’s diagnosis and treatment of infectious diseases.

The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th February 2020 in San Diego, CA would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics areas. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

What are the essentials being missed out on? What is the real role of probiotics strains, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis?

Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.

With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year’s congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.

Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon. The conference will address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.

Improving clinical translation in neuroscience research has always been a major challenge until now. There are many research collaborations happening in the neuroscience space today for neurodegenerative disorders research. The conference will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims to bring in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries.

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.

Drug product development for highly potent APIs (HPAPIs) can be challenging. Complications with the interface between operations in drug substance and drug product handling can result in increased program complexity and cost. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine. This year’s conference will focus on case studies related to development, rapid scaling, validation and commercial production of HPAPI drug substance, as well as integrated containment requirements for particle engineering and drug product.

Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon.

The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th-8th February 2019 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

The next big question in cancer immunotherapy is what’s next in immuneoncology?
Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.

Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors